5.89

15.26% +0.78

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Discussions Forecast

Black Diamond Therapeutics Inc stock is currently priced at $5.89, with a 24-hour trading volume of 566.43K. It has seen a +15.26% increased in the last 24 hours and a +15.72% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.06 pivot point. If it approaches the $5.38 resistance level, significant changes may occur.

Previous Close:

$5.11

Open:

$5.16

24h Volume:

566.43K

Market Cap:

$304.62M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-2.5833

EPS:

-2.28

Net Cash Flow:

$-66.75M

1W Performance:

+11.98%

1M Performance:

+15.72%

6M Performance:

+213.30%

1Y Performance:

+300.68%

1D Range:

$5.16

$5.95

52W Range:

$1.43

$6.85

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

617 252 0848

Address

One Main Street, 10th Floor, Cambridge, MA

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

BDTX's Discussions on Twitter

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?

Zacks Investment Research

Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know

Zacks Investment Research

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

GlobeNewswire Inc.

Wall Street Breakfast: The Week Ahead

Seeking Alpha

How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%

Zacks Investment Research

Black Diamond Therapeutics Inc Stock (BDTX) Financials Data

Black Diamond Therapeutics Inc (BDTX) Net Income 2024

BDTX net income (TTM) was -$82.44 million for the quarter ending December 31, 2023, a +9.57% increase year-over-year.

Black Diamond Therapeutics Inc (BDTX) Cash Flow 2024

BDTX recorded a free cash flow (TTM) of -$66.75 million for the quarter ending December 31, 2023, a +21.72% increase year-over-year.

Black Diamond Therapeutics Inc (BDTX) Earnings per Share 2024

BDTX earnings per share (TTM) was -$1.88 for the quarter ending December 31, 2023, a +25.40% growth year-over-year.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.